edema, determined by a modified version of the Kansas City Cardiomyopathy Questionnaire (KCCQ). 3 The prevalence of these symptoms was greater in persons with poorer kidney function. However, it is not known whether these symptoms precede the development of clinically apparent HF or are the result of pathophysiologic changes because of CKD. To better understand the relationship of symptoms characteristic of HF with new onset of HF that required hospitalization in patients with CKD, we studied participants enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study.
Methods Participants
The CRIC Study was established in 2001 as a prospective observational cohort study to evaluate the determinants of progression to endstage renal disease and occurrence of cardiovascular disease among persons with CKD. 4, 5 Participants were recruited from 7 clinical centers between June 2003 and August 2008. Inclusion criteria were an estimated GFR between 20 and 70 mL/min per 1.73 m 2 for persons aged 21 to 44 years, 20 to 60 mL/min per 1.73 m 2 for persons aged 45 to 64 years, and 20 to 50 mL/min per 1.73 m 2 for those aged 65 to 74 years. Exclusion criteria included previous transplantation, polycystic kidney disease, multiple myeloma, use of immunosuppression, and severe comorbid illnesses, such as cirrhosis, HIV disease, and severe HF, defined as New York Heart Association (NYHA) class III or IV HF at baseline. The study was reviewed and approved by the Institutional Review Board at each participating clinical center. HF at study entry was assessed by participant response to the question at baseline: have you ever been diagnosed with or has a doctor or other health professional ever told you that you have HF? Of 3520 participants who completed the year 1 visit, we excluded 404 participants who reported HF at baseline and 23 who were missing year 1 KCCQ score. For this analysis, we included 3093 participants who did not report a history of HF and who completed the KCCQ at year 1 of follow-up.
Predictors
The predictor was the annually updated KCCQ score. The KCCQ is a validated instrument to assess health status among persons with HF. 6 The self-administered questionnaire includes 23-items, which quantify the importance of dyspnea, fatigue, and edema on physical, social, and emotional functions. The responses are categorized under 3 subscales (symptom burden, physical limitation, and quality of life) with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The total KCCQ score represents the mean of the 3 subscale scores. We modified the KCCQ by omitting reference to the participant having existing HF, thereby allowing administration of the instrument to persons with and without diagnosed HF; the scoring was not changed by this modification (Data Supplement). The KCCQ was administered as a written form in person during annual study visits to participants beginning 1 year after enrollment and each year thereafter. The questionnaire was read aloud to participants with poor literacy and their verbal responses were recorded. The KCCQ scores were not forwarded to the participants' clinical providers.
Outcomes
The primary study outcome was the first hospitalization for HF from study entry until the administrative censoring date of March 31, 2011. Study participants were queried every 6 months if they were hospitalized and selected hospitals or healthcare systems were queried for qualifying encounters. The first 30 discharge codes were identified for all hospitalizations, and codes relevant to HF resulted in retrieval of medical records by study personnel for centralized adjudicated review. At least 2 study physicians reviewed all possible HF events using medical records and guidelines on clinical symptoms, radiographic evidence of pulmonary congestion, physical examination of the heart and lungs and, when available, central venous hemodynamic monitoring data, and echocardiographic imaging. HF was confirmed when both reviewers agreed on a probable or definite occurrence of HF based on modified clinical Framingham criteria.
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Covariates
Covariates evaluated at baseline included demographic characteristics (age, sex, and race/ethnicity); clinical characteristics (body mass index, systolic and diastolic blood pressure, hypertension, diabetes mellitus, current smoking, alcohol use, and coronary artery disease [previous myocardial infarction or revascularization]); hemoglobin level, low-and high-density lipoprotein levels, cardiac troponin T (TnT), measured using the highly sensitive assay on the Elecsys 2010 analyzer (www.roche-diagnostics.us), and N-terminal pro-B-type natriuretic peptide (NT-proBNP), measured using the Elecsys 2010 analyzer (www.roche-diagnostics.us); 24-hour urine protein and estimated glomerular filtration rate (eGFR) using both creatinine and cystatin C. 8 Trans-thoracic echocardiography was performed in all CRIC participants at year 1 of follow-up according to the American Society of Echocardiography guidelines 9 and the data were sent to the CRIC core echocardiography laboratory for measurement and analysis. Left ventricular (LV) geometry, mass, and systolic and diastolic function, evaluated using M-mode, 2-dimensional and Doppler echocardiography, were included as covariates in cross-sectional analyses. LV mass was calculated using the area-length method and indexed to height 2.7 . 9 LV hypertrophy (LVH) was defined as LV mass/height 2.7 ≥47 g/m 2.7 in women and ≥50 g/m 2.7 in men. 10 LV end-diastolic and end-systolic volumes were calculated using the modified biplane method and ejection fraction was calculated as: (end-diastolic volume−end-systolic volume)/end-diastolic volume. LV systolic dysfunction was defined as an ejection fraction <0.45. [11] [12] [13] [14] Mitral inflow E-and A-wave velocities, E-wave deceleration time and pulmonary venous reverse A-wave duration were used to categorize LV diastolic function into normal, mildly, moderately or severely abnormal. 15 Because 1 center was unable to evaluate diastolic function, these measures were unavailable in 564 participants.
Statistical Analysis
We categorized KCCQ scores into quartiles to examine for any trends without imposing prespecified cut-points. 3 In addition, KCCQ score was dichotomized at the clinically relevant cut-off value of 75 and was modeled as a continuous variable per 10 points and after logtransformation because of its skewed distribution. Baseline demographic and laboratory values and year 1 echocardiographic values were compared across categories of the first KCCQ score using the ANOVA or Kruskal-Wallis test for continuous variables and χ 2 test for categorical variables. We also compared baseline characteristics of the participants who were included in this study and the participants without a history of HF who were not included. The incidence of HF was calculated for each quartile of the first KCCQ score. Before evaluating the association of the first KCCQ score with time to incident HF events, we tested the proportional hazards assumption and found that it was violated. We then proceeded to study the association between the annually updated KCCQ score and incident HF in the 1-year period after the last KCCQ administration using repeated measure logistic regression. For the annually updated KCCQ score, we began with a demographically adjusted model (age, sex, race/ethnicity, and site) and then created a clinically adjusted model (age, sex, race/ethnicity, site, diabetes mellitus status, history of cardiovascular disease, current smoking and alcohol use, body mass index, systolic blood pressure, low-density and high-density lipoprotein levels, 24-hour urine protein, and eGFR). We then further adjusted for baseline NT-proBNP concentrations. In a final step, we fully adjusted the model by including LVH and LV systolic dysfunction at baseline as covariates. We repeated these analyses with the annually updated KCCQ score dichotomized at a cut-point of 75. In a clinically stable population with advanced HF, a score >75 has been used to define good health status, and ≤75 as clinically significant HF symptoms. [16] [17] [18] All covariates included in the multivariable-adjusted models, except NT-proBNP concentration, were also time-updated. We also evaluated the unadjusted time-updated association of each of the subscales of the KCCQ (symptom burden, physical limitation, and quality of life) with incident HF. Of the total number of participant visits, including the year 1 visit, follow-up KCCQ data were missing for 2.1%. Participants were censored on death or development of endstage renal disease with initiation of hemodialysis. STATA version 11 (StataCorp, www.stata.com) was used for the analysis.
Results
The participants' ages ranged from 22 to 76 years at the year 1 assessment. Participants in the lowest quartile of the first KCCQ scores were more likely to be female and black and had a higher prevalence of diabetes mellitus, current smoking, and cardiovascular disease, but a lower prevalence of alcohol use (Table 1) . Participants in the lowest quartile of KCCQ scores also had higher body mass index, systolic blood pressure, urine protein, NT-proBNP and TnT concentrations, and lower eGFR, hemoglobin and high-density lipoprotein concentrations. The 427 participants who were not included in this study because of a history of HF or missing year 1 KCCQ data were more likely to be older and black had worse kidney health and had a higher prevalence of comorbidities (Table I in the Data Supplement).
Compared with those with the first KCCQ scores in the highest quartile, participants in the lowest quartile had a significantly higher mean LV mass index and a 2-fold greater prevalence of LVH ( Table 2 ). The prevalence of LV systolic and diastolic dysfunction, however, did not differ significantly across quartiles of KCCQ scores.
Over a mean±SD (range) follow-up period of 4.3±1.6 years (0.7-6.7 years), 211 new HF hospitalizations were identified. The rate of new HF hospitalization decreased as the quartile of first KCCQ score increased (Table 3) .
The median number of annual KCCQ assessments per participant was 5 (interquartile range, [3] [4] [5] [6] . Participants with annually updated KCCQ scores within the first and second quartiles were at significantly greater risk of incident HF hospitalization in the following year in demographically adjusted models (Table 4 ). In the fully adjusted model that included baseline NT-proBNP level, LVH and LV systolic dysfunction as covariates, participants within the lowest quartile were at 3.3-fold risk for incident HF hospitalization in the following year ( 
Discussion
In patients with CKD, we found that HF symptoms are associated with the initial hospitalization for HF within the upcoming year, independent of all covariates including NT-proBNP and with objective measures of subclinical cardiac disease, including LVH. Our study, therefore, takes the important step of linking common preclinical HF symptoms with near-term risk of HF hospitalization in the setting of CKD.
Although CKD is a strong and independent predictor of incident HF, 19 there are currently no established strategies for identifying patients at high risk for HF or preventing the onset of HF in patients with CKD. We had previously reported a high prevalence of symptoms characteristic of HF-dyspnea, fatigue, and edema-as assessed by the modified KCCQ among patients with moderate-to-severe CKD without a previous self-reported diagnosis of HF. 3 This study expands the literature by demonstrating that the KCCQ score independently predicts incident HF in the near-term in an at-risk population.
Previous studies have studied the KCCQ primarily in HF populations, 18, 20 comparing and correlating the KCCQ score with natriuretic peptide concentrations and left ventricular ejection fraction, 21, 22 and used it as an outcome. 23 The KCCQ has recently been validated to monitor health-related quality of life in patients with severe aortic stenosis and NYHA class II-IV symptoms undergoing transcatheter aortic valve replacement. 24, 25 However, our study is the first to evaluate the association between KCCQ score and incident HF in a population without diagnosed HF and, thereby, extends the application of the KCCQ to the pre-HF setting.
Symptom burden as assessed by the KCCQ is a known predictor of recurrent HF events and death in patients with chronic HF. 18, 26 In this study, the initial assessment of symptoms characteristic of HF was strongly associated with incidence of HF hospitalization during follow-up. However, the proportional hazards assumption was violated when the initial KCCQ score was evaluated in multivariable analyses. Therefore, we modeled KCCQ score as a time-updated variable and found that, when repeated annually, the KCCQ score had a strong association with incident HF hospitalization, independent of all time-updated covariates. In addition, the time-updated subscales of the KCCQ, including symptom burden, physical limitation, and quality of life, had similar associations with incident HF, suggesting that these symptoms heralding incipient HF in patients with CKD negatively impact multiple facets of daily life. Our findings suggest that these clinical symptoms in patients with CKD are a clear harbinger of risk for de novo HF hospitalization. Moreover, in the clinical setting, the association of the lowest quartile of KCCQ score with ≈7-fold risk of hospitalization for HF in unadjusted analyses may be more relevant to the evaluation of risk than the epidemiological finding of a 3.3-fold risk in the fully adjusted model. Therefore, in this high-risk population, screening for symptoms characteristic of HF may provide an opportunity for early diagnostic and therapeutic interventions to prevent acute HF leading to hospitalization.
We had reported previously strong associations of NT-proBNP and TnT with LVH in the CRIC study. 27, 28 In this study, we determined that the KCCQ score was associated cross-sectionally with NT-proBNP and TnT concentrations, LV mass index and LVH prevalence. In contrast, there was no significant association between KCCQ score and LV systolic and diastolic dysfunction. Like NT-proBNP and TnT, symptoms characteristic of HF are linked with LVH. The associations of symptoms with increased LV mass and NT-proBNP suggest that increased LV mass and elevated LV filling pressures may contribute to the symptoms characteristic of HF among patients with CKD. However, the association between the lowest quartile of KCCQ score and incident HF hospitalization remained significant despite adjustment for baseline NT-proBNP level and LVH.
Although distinguishing HF from volume overload because of worsening kidney disease can be challenging, the adjudication process for HF hospitalization in the CRIC Study was designed to be as specific as possible. Moreover, only a small percentage of participants were hospitalized for HF, suggesting that CKD and HF were not necessarily coterminous in this cohort. Also, participants with worsening kidney disease, who eventually developed end-stage renal disease, were eliminated from the cohort on initiation of hemodialysis. Finally, in the fully adjusted repeated measure logistical regression model, the association between KCCQ score and HF hospitalization remained significant despite adjustment for measures of worsening kidney function, including timeupdated 24-hour urine protein and eGFR.
Our study has several strengths. We studied a large, wellcharacterized cohort with CKD. The primary outcome of incident HF was adjudicated using established criteria. 7 The KCCQ score and a large number of covariates of interest, including eGFR and 24-hour protein urine, were repeatedly assessed, permitting time-updated covariates to be included in our statistical models. Some limitations of our study should be considered. HF at study entry was assessed by self-report; it is possible that some participants may have been incorrectly classified as either having or not having HF. In addition, new cases of HF were identified initially by hospitalization. Therefore, participants who were diagnosed with HF in an ambulatory care setting would be missed. The modification of the KCCQ by the removal of reference to existing HF allowed us to administer the instrument to participants with and without diagnosed HF. However, it is possible that this modification may limit the translatability of our findings to the unmodified KCCQ. Finally, although the symptoms characteristic of HF were strongly associated with HF hospitalization, we could not evaluate whether they may be predictive of other types of hospitalization as well. It is possible that the symptoms reflect a global deconditioning rather than a specific predisposition to HF.
In conclusion, symptoms characteristic of HF independently predict the de novo hospitalization for HF within the following year in patients with CKD without a history of HF. They are also associated with subclinical manifestations of HF. Assessment of symptoms such as dyspnea, fatigue and edema may be a simple and low cost method of identifying patients at higher risk for HF to target for earlier intervention. 
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